The U.S. Food and Drug Administration (FDA) granted approval for Abbreviated New Drug Application (ANDA) number ANDA091665 on June 30, 2014.
The approved product is ARGATROBAN injection, a human prescription drug classified as an anti‑coagulant and direct thrombin inhibitor. It is supplied as a 250 mg/2.5 mL (100 mg/mL) injectable solution for intravenous administration.
The application was submitted by PH HEALTH, with manufacturing by Par Health USA, LLC. The product is listed under the National Drug Code (NDC) 42023‑182‑89 and 42023‑182‑01.
Actualités réglementaires16 sept. 2026•3 min de lecture
FDA Approves ARGATROBAN Injection (ANDA091665)
The FDA has approved ANDA091665 for ARGATROBAN injection, a prescription anticoagulant submitted by PH HEALTH.
Compilé par l'équipe Pharmacountry · Source : FDA.gov
Sujets :
Évaluations
(0)
(0)
(0)
(0)
(0)
Laissez votre note